Aytu BioPharma to Present at Upcoming September 2025 Conferences

Rhea-AI Summary

Aytu BioPharma (Nasdaq:AYTU), a pharmaceutical company specializing in innovative medicines for complex central nervous system diseases, has announced its participation in two upcoming investor conferences in September 2025.

Management will present at the MicroCap Rodeo Fall Conference in New York City on September 25, 2025, at 2:00 PM ET, and at the virtual Lytham Partners Fall 2025 Investor Conference on September 30, 2025, at 2:45 PM ET. Both presentations will be available via webcast, and management will conduct one-on-one meetings during both events.

DENVER, CO / ACCESS Newswire / September 24, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced management will participate at the following investor conferences:

MicroCap Rodeo Fall Conference

Date: Thursday, September 25, 2025
Location: New York City
Presentation Time: 2:00 p.m. Eastern time
Webcast: https://www.webcaster5.com/Webcast/Page/3142/53024

Lytham Partners Fall 2025 Investor Conference

Date: Tuesday, September 30, 2025
Location: Virtual
Presentation Time: 2:45 p.m. Eastern time
Webcast: https://app.webinar.net/K8vDlaelmAd

Management will be participating in one-on-one meetings throughout both events. To arrange a meeting with management, please contact Robert Blum of Lytham Partners at aytu@lythampartners.com.

About Aytu BioPharma

Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), and a line of legacy products, including Karbinal® ER (carbinoxamine maleate), Poly-Vi-Flor® and Tri-Vi-Flor®. To learn more, please visit aytubio.com.

Contacts for Investors

Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
rselhorn@aytubio.com

Robert Blum
Lytham Partners
aytu@lythampartners.com

SOURCE: Aytu BioPharma, Inc.

View the original press release on ACCESS Newswire

FAQ

When and where will Aytu BioPharma (AYTU) present at the MicroCap Rodeo Fall Conference 2025?

Aytu BioPharma will present at the MicroCap Rodeo Fall Conference in New York City on September 25, 2025, at 2:00 PM Eastern time.

How can investors access Aytu BioPharma's (AYTU) Lytham Partners Fall 2025 conference presentation?

Investors can access the virtual presentation through the webcast link: https://app.webinar.net/K8vDlaelmAd on September 30, 2025, at 2:45 PM ET.

How can investors arrange one-on-one meetings with Aytu BioPharma (AYTU) management?

Investors can arrange one-on-one meetings by contacting Robert Blum of Lytham Partners at aytu@lythampartners.com.

What is Aytu BioPharma's (AYTU) business focus?

Aytu BioPharma is a pharmaceutical company focused on developing innovative medicines for complex central nervous system diseases to improve patient quality of life.